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Background: Rotavirus gastroenteritis (RVGE) is a frequent disease in young children. The recommended German
paediatric immunisation schedule does not currently include rotavirus vaccination. A lack of economic data on the
impact of routine vaccination is stated as one of the reasons. As a result, the current coverage rate is low, around
26%. This study investigated whether rotavirus vaccination using the two-dose rotavirus vaccine RIX4414 (RotarixW,
GlaxoSmithKline Vaccines) would be a cost-saving intervention from the perspective of the statutory health insurance
(SHI) in Germany.
Objective: The objective of the study was to analyse health outcomes (number of RVGE cases and hospitalisations
prevented) and the associated cost to the SHI when comparing 100% rotavirus vaccination with no vaccination
in Germany.
Methods: A Markov cohort model simulated the number of RVGE events and related costs in a German birth
cohort over the first 60 months of life with current disease management. The model compared an unvaccinated
cohort with a fully vaccinated cohort. Vaccine efficacy data from international clinical trials were combined with
German-specific epidemiological and cost data. Results were tested using extensive sensitivity analyses.
Results: Full vaccination of a birth cohort against rotavirus disease would be expected to prevent 82% of RVGE
cases, reducing RVGE frequency from 28 to 5 events per 100 children in the birth cohort up to age 5 years. The
estimated cost reduction with vaccination for that period is predicted to be €9.2 million with 100% coverage
(€6.9 million with 75% coverage), mainly due to reductions in SHI reimbursement for productivity losses, hospital
stays and visits to office-based physicians due to the vaccine’s efficacy against severe disease.
Conclusions: Routine rotavirus vaccination in Germany would reduce the number of hospitalised and outpatient
cases. The associated investment could be fully offset by costs avoided in hospital stays, physician visits and SHI
reimbursement of productivity losses. Sensitivity analysis indicated that vaccination would be cost-saving in 95%
of simulations. Incremental cost was observed only under extreme conditions, especially when the time spent at
home due to rotavirus disease was low or when vaccine efficacy against severe disease was heavily decreased.
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Rotavirus is the leading cause of acute gastroenteritis
(AGE) in young children [1,2]. The virus is highly conta-
gious and is usually transmitted by the faecal-oral route [3].
Seventy per cent of children are infected at least once be-
fore the age of 5 years [4-6], and a much lower proportion
are infected three to four times over the same age range.
The first infection is the most severe, especially when it* Correspondence: christoph.c.mair@gsk.com
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2013occurs at a very young age when natural immunity is not
well developed [6]. The disease burden of rotavirus gastro-
enteritis (RVGE) arises from the combination of a high inci-
dence rate, severity of symptoms leading to hospitalisation
(particularly in very young infants), and the consequent dis-
tress caused to children and other family members.
In the European Union rotavirus is estimated to cause
more than 200 deaths each year, over 87,000 hospital
admissions, and almost 700,000 outpatient visits in
children under the age of 5 years [7]. The burden of
the disease in Germany is well documented throughopen access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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[11,12], and a family impact study [13]. According to
the Robert Koch Institute, RVGE is the most frequent
registered disease in children aged <5 years in Germany,
with over 612,000 reported rotavirus infections since
2011 [14].
Two oral rotavirus vaccines are currently available for
the prevention of rotavirus infection in Germany: a
two-dose monovalent human rotavirus vaccine RIX4414
(RotarixW)a and a three-dose pentavalent bovine-derived
vaccine (RotaTeq™)b, both available since 2006. The oral
live attenuated human rotavirus vaccine RIX4414 contains
only one strain, G1P[8]. Two doses of the vaccine have
been shown to be highly immunogenic, well-tolerated and
protective against RVGE [15-18].
Several German federal states have already issued
recommendations for rotavirus vaccination and a number
of statutory health insurance (SHI) funds grant re-
imbursement for rotavirus vaccination [19]. However,
rotavirus vaccination is not part of the federal German
recommended immunisation schedule. As a result, the
overall vaccination coverage rate is low with large
regional variation [20]. The coverage rate among children
aged less than 2 years was only 26% in 2010 [20].
The economic value of rotavirus vaccination has been
investigated in many countries in the developed world,
but there is controversy about the conclusions of the
analyses [21]. The lack of country-specific economic
analysis from the SHI perspective for Germany has
been stated by the Ständige Impfkommission (Standing
Committee on Vaccination [STIKO]) of the Robert Koch
Institute as one reason why the vaccine is not included on
the list of recommended vaccinations for childrenc.
Earlier evaluations have shown that rotavirus vaccination
in Germany could be a cost-saving intervention from a
societal perspective, but only very limited data are
available from the SHI perspective [22-24]. The analysis
presented here evaluates the impact of rotavirus vaccinationFigure 1 Rotavirus diarrhoea episodes as a function of age. Distributio
birth cohort of 2008.on healthcare resource use and the associated economic
impact from the perspective of a third-party payer. In
Germany, incremental cost-effectiveness ratios (ICERs)
are not used in economic evaluations of pharmaceuticals,
nor are they established as standardised thresholds for
recommendations by STIKO. Therefore we have presented
health outcomes (RVGE cases prevented) and cost results




A Microsoft Excel-based Markov cohort model has been
used to compare predicted outcomes and costs between
full vaccination (100% coverage) and no vaccination.
The model has been described previously and reported
elsewhere [25]. It follows the German birth cohort of
2008 (n = 682,514) until the cohort reaches 5 years of
age, with a time cycle of one month (60 cycles in total).
It has been adapted to the German natural death rate
for children aged 0–5 years and to German treatment
pathways. In each monthly cycle the cohort is exposed
to the risk of experiencing a first episode of rotavirus
diarrhoea. The risk is age-dependent over the age range
modelled (0–5 years) and follows a Weibull distribution
(coefficients 1.5 for the shape and 24.2 for the scale),
with a shift to the right ending in a long tail (Figure 1).
An episode of RVGE may result in a visit to a medical
practitioner in an office-based setting, hospitalisation
(i.e. a visit to the emergency room followed by hospitalisa-
tion), or staying at home and watchful waiting without
consulting a medical practitioner. Visits to office-based
physicians can be followed by hospitalisation. This is
consistent with the findings of the REVEAL study, in
which 33-68% of children with AGE who first presented
to primary care subsequently required additional medical
care in another setting [26]. Informal care at home after
hospitalisation does not require a further visit to ann of rotavirus diarrhoea episodes as a function of age in the German
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occur due to RVGE.
Any child aged under 5 years may be exposed to
another RVGE after the first episode. Repeated rotavirus
infections have been shown to induce progressive natural
immunity that protects against subsequent infections
[6], and therefore second and subsequent infections are
unlikely to be severe. Thus we assumed that the second
RVGE event can be treated by an office-based physician
and never leads to an emergency visit or hospitalisation.
During the first months of life a reduced number of
RVGE episodes is observed, compared with older infants
and children, as a result of protection conferred by
circulating maternal antibodies [27-29]. However, as
they are unprotected by natural immunity, children
hospitalised for a non-rotavirus-related event are at
risk of acquiring nosocomial rotavirus infection. The
model accounts for both these aspects.




This analysis compares 100% vaccination with no vaccin-
ation. To assess the no-vaccination condition, the model
has been populated with epidemiological data reflecting
the German situation in 2008 when the rotavirus vaccine
coverage rate was very low, no more than 10%. The
input data are summarised in Table 1. Model transition
probabilities as a function of age for monthly time units
are generated by calibrating the model to fit German
data for numbers of community-acquired RVGE cases,
outpatient physician visits, hospital stays, nosocomial
RVGE cases, and RVGE-specific deaths. We selected
the birth cohort of 2008 as a reference [30] instead of
an average over several years in order to allow for the
decreasing trend in number of births over time in
Germany, and because 2008 was the last year in which
the proportion of rotavirus-vaccinated children was <10%.
The initial data inputs for the model were entered as
a proportion of the birth cohort exposed to the risk of
developing rotavirus diarrhoea for the time period from
birth to the age of 5 years. For example, approximatelyTable 1 Epidemiological data for a birth cohort of 682,514 in
Parameter Proportion of birth cohort
Total RVGE cases 28.10%
Untreated RVGE cases 6.20%
Outpatient-treated RVGE cases 21.90%
Hospital-treated RVGE cases 4.93%
Nosocomial RVGE cases 0.41%
Deaths
RVGE rotavirus gastroenteritis.29% of the birth cohort will experience rotavirus diarrhoea
before the age of 5 years, and the distribution of these
disease episodes as a function of age follows the curve
shown in Figure 1. A similar exercise was performed
for medical visits, hospitalisations, nosocomial RVGE,
and RVGE-specific deaths.
The estimated proportion of the birth cohort developing
RVGE between the age of 0 and 5 years in Germany is
the sum of the proportion attending primary care settings
for RVGE plus the proportion of parents who do not
take their child suffering from any kind of diarrhoea to
a physician.
Based on the annual number of AGE cases (Diagnosis-
related group [DRG]: A08.0, A08.4 and A09) in the Federal
Health Report in the age group 0–5 years between 2000
and 2008 [35], the average proportion of the birth cohort
hospitalised for an AGE event is 8.65%. As AGE cases are
not routinely tested for rotavirus, the reported number
of RVGE cases should be seen as an underestimate. The
reported numbers result in an annual incidence of 1.10
per 100,000 children aged 0–5 years, while other studies
report much higher country-specific annual incidence
rates, up to 4.680 per 100,000 [1,8-10,14]. The REVEAL
[10] and SHRIK [9] studies reported that RVGE infections
accounted for up to 66% of all hospitalised AGE cases. In
the absence of reliable reported data, we used these num-
bers to estimate RVGE cases. In the base case we assumed
that RVGE cases accounted for 57% instead of 66%. The
range tested in sensitivity analysis was from 42% to 66%.
The available data for nosocomial RVGE events have
some limitations, as the studies are either based on re-
ported cases only or are derived from a single centre,
and provide different estimates for the same age group
(between 0 and 5 years old) [31-33]. We selected the
lowest estimate, 0.41% of the birth cohort, as the base-case
value for nosocomial RVGE.
The Federal Statistical Office of Germany reported one
death due to RVGE in the relevant age group in 2006 [34],
and that value has been included in the model.
Vaccine efficacy data
In the absence of country-specific studies, vaccine effi-
cacy (VE) data for RIX4414 were collected from thefants





2 795 Calculated from different sources [31-33]
1 [34]
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six European countries that was the basis for the approved
Summary of Product Characteristics for RotarixW [36,37].
Jit et al. [38] summarised vaccine efficacy results after a
first and second dose for rotavirus diarrhoea of three
severity levels: mild (no medical visit), moderate (medical
visit), and severe (hospitalisation). These severity levels
were also used in the model. Confidence intervals for each
VE value were estimated using the technique of Wilson
[39], as proposed by Newcombe [40]. They were used
in the sensitivity analyses, where the range was from a
minimum of 69.4% for VE against mild disease after the
first dose to a maximum of 100%. In sensitivity analysis,
the model also takes into account the change in VE over
time as measured in the European trial.
Using data from a European trial in a model for
Germany implicitly assumes that the rotavirus genotype
distributions in Germany are comparable with those
in the countries in the trial. Although the diversity of
rotavirus strains co-circulating in the European population
is high, this assumption is appropriate based on a
review of the available literature. The published data
show that the genotype combinations, distributions and
observed trends in Germany are comparable with those
in the European region [41-44].Cost-related data
Unit costs were assigned reflecting the perspective of
the statutory health insurance (SHI) with a reference
year of 2011. Cost inputs are summarised in Table 2.
They include productivity losses of parents as far as
they are reimbursed by the SHI (70% of net income of
each parent from day 1 when the medical event begins
until day 9) [45]. Because precise data on the number
of parents utilising this option of reimbursement areTable 2 Cost data
Item Proportion Value
Consultation of office-based physicians 42 €
Outpatient medication 5 €
Hospitalisation 1 675 €
Hospital stay for 1 parent (children aged <8 years) 45 €/da
Nosocomial cases 439 €
SHI-reimbursed productivity loss 78 €/da
Proportion of families with productivity loss
(both parents working)
31%
Days staying at home for an outpatient-treated RVGE 5.3 days
Days staying at home for hospitalised RVGE 5 days
Vaccine costs per dose 51 €
Administration costs per dose 6 €
DRG Diagnosis-related group, EBM Einheitlicher Bewertungsmaßstab (Doctors’ fee slacking, SHI reimbursement has been approximated in
the model using the average salary of a woman aged
20–35 years in Germany. This can be considered as a
conservative approach, as a gender payment gap re-
mains in many countries in Europe, including Germany
[46]. No cost from the SHI perspective is considered
for untreated cases. The Federal Statistical Office of
Germany reports that 28% of mothers with children
aged less than 3 years and 55% of those with children
aged between 3 and 5 years old were working in 2008
[47]. It is assumed that only families with both parents
working would request SHI reimbursement for prod-
uctivity loss.
For the base case we took into account the age-specific
probabilities of RVGE in the age group of children less
than 5 years old and calculated a weighted average of
the proportion of families in which both parents were
working (31%). The range tested in sensitivity analyses
was 10 to 55%. The duration of hospitalisation for children
with RVGE was 5 days [26]. The reported average number
of workdays lost was 5.3 days for children with RVGE
treated in primary care [11]. As the studies [11,26]
provided no confidence interval for these values, we
assumed that both the duration of hospitalisation and
for staying at home ranged between 2 and 7 days in
sensitivity analyses.
Increased duration of hospitalisation due to nosocomial
rotavirus infection varied between 1.7 and 5.9 days in the
study of Gleizes et al. [55]. The base case evaluation used
a value of 2 days, with sensitivity analysis ranging from 1
to 4 days. Data on the number of days at home due to
hospitalisation were taken from the Institute for the
Hospital Remuneration System [56].
A monthly discount rate was applied to all costs and
economic benefits, set at a value that equates to 3% per
year [57].Source
EBM 2011 codes 3110 and 4110 [48]
Dimenhydrinate and paracetamol, taking into account reductions




y 70% of average salary for women (aged 20–35 years) [52]
Average of reported data from 0–3 year age group and 4–5 year age
group weighted by the incidence of RVGE in these age groups [47,53]
REVEAL study data for Germany [11]
Average length of hospital stay, REVEAL study data for Germany [26]
RotarixW 10-dose package taking into account mandatory rebates [49]
Regional contracts (e.g. “Barmer GEK”) [54]
cale), RVGE rotavirus gastroenteritis, SHI statutory health insurance.
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One-way sensitivity analysis was conducted to account for
the uncertainty in the data due to a lack of unequivocal
reference values. In addition to conducting one-way
sensitivity analysis on the cost difference, we also inves-
tigated sensitivity using probabilistic sensitivity analyses
(PSA) on those variables that indicated an impact on
the cost result after performing the one-way sensitivity
analysis. This allowed us to limit the number of variables
selected for this analysis. PSA results indicate the range
over which variables may fluctuate and the probability
that vaccination leads to cost savings. Distributions
were assigned to the tested variables (Table 3). Some
variables have a normal distribution assigned to their
spread of values. These are mainly the vaccine efficacy
parameters, together with the age-specific incidence
rate of diarrhoea. Second-order Monte Carlo simulations
were run with @RISK software (Palisade, UK, 2011). Up
to 5000 iterations were performed to obtain the cost
distribution results.
We used regression analysis to evaluate whether the
same variables influence the cost-difference results in PSA
as in the one-way sensitivity analysis.Results
Base case
The model predicted that full vaccination of the birth
cohort of 2008 (n = 682,514) with RIX4414 would have
the potential to prevent 134,396 medically treated
community-acquired RVGE cases and 22,438 home-Table 3 Variables and their distribution values used in PSA te
Variable
Average number of days staying at home after consultation visit
Average number of days staying at home due to hospitalisation
Average number of days staying at home due to nosocomial rotavirus infect
Proportion of families with both parents working
Proportion seeking medical advice
Probability of hospitalisation
Probability of nosocomial infection in the first year
Vaccine efficacy for mild RVGE, 1 year, 1 dose
Vaccine efficacy for moderate RVGE, 1 year, 1 dose
Vaccine efficacy for severe RVGE, 1 year, 1 dose
Vaccine efficacy for mild RVGE, 1 year, 2 doses
Vaccine efficacy for moderate RVGE, 1 year, 2 doses
Vaccine efficacy for severe RVGE, 1 year, 2 doses
Age-specific incidence rate of diarrhoea
Vaccine coverage rate
Discount rate on cost
PSA probabilistic sensitivity analysis, RVGE rotavirus gastroenteritis.treated cases during the first five years of life. This cor-
responds to a decrease of almost 82% in RVGE cases,
from 192,037 (28% of the birth cohort) to 35,203 cases
(5%). Consultations with office-based physicians would
be expected to decrease from 149,544 (22%) to 15,148
(2.2%), and hospitalisations from 33,648 (5%) to 527
(0.077%). Nosocomial infections would also be ex-
pected to decrease, from 2,795 (0.41%) to 238 events
(0.035%).
Table 4 shows the cost from the SHI perspective for
both scenarios, no vaccination and full vaccination of
the birth cohort. Full vaccine coverage would be expected
to lead to a potential cost saving of €9.2 million overall
for the SHI, when direct medical costs and indirect
costs are both included. This is due to the large reduction
in RVGE events, leading in turn to a substantial decrease
in hospitalisations and consultations with office-based
physicians, saving approximately €60 million and €6
million in direct medical costs, respectively, and approxi-
mately €64 million and €21 million, respectively, when
indirect costs are also included (Table 4). In the cohort
with full vaccination, the largest cost segment is the cost
of vaccination, at €77.4 million including administration
costs. The SHI reimbursement cost for productivity losses
incurred by parents represents a large part of the cost,
up to €18 million without vaccination and decreasing
to €0.9 million with full vaccine coverage. Overall, the
cost offsets in reductions in direct medical cost and
SHI reimbursement cost for productivity losses would
be expected to exceed the cost of vaccination in the
base case, thus resulting in a net saving for the SHI.sting
Distribution type Mean Source
General (2,3,4,5,6,7; 0.05,0.05,0.15,0.2,0.3,0.25) 5.2 [11]
General (2,3,4,5,6,7; 0.05,0.02,0.02,0.25,0.25,0.05) 4.6 [56]
ion Gamma (2,1) 2 [26]
Normal (0.31, 0.031; truncated 0.1,0.55) 31% [47]
Beta general (6.5,7; 0.65,0.9) 77% [1]
Beta general (10,5; 0.17,0.26) 23% [9]
Beta general (6,4; 0.01,0.048) 3.28% [31-33]
Normal (0.784; 0.03) 0.784 [36,38]
Normal (0.808; 0.03) 0.808 [36,38]
Normal (0.900; 0.03) 0.900 [36,38]
Normal (0.871; 0.03) 0.871 [36,38]
Normal (0.898; 0.03) 0.898 [36,38]
Normal (1.000; 0.1; truncated (0.871; 1) 0.94 [36,38]
Normal (0.023; 0.0023) 0.023
Uniform (0.75;1) 87.5%
Discrete (0,0.75,1,1.5) 3%
Table 4 Cost impact of vaccination
Cost item No vaccination Vaccination Difference
Direct medical cost only
Vaccine cost € 77 424 462 € 77 424 462
Consultation medical visit € 6 748 676 € 686 730 -€ 6 061 946
Hospitalisation € 61 456 155 € 1 000 252 -€ 60 455 903
Nosocomial infection € 1 200 255 € 104 523 -€ 1 095 732
Total € 9 810 880
Direct medical cost plus indirect cost*
Vaccine cost € 77 424 462 € 77 424 462
Consultation medical visit € 23 886 005 € 2 430 584 -€ 21 455 421
Hospitalisation € 65 054 063 € 1 058 811 -€ 63 995 253
Nosocomial infection € 1 330 780 € 115 890 -€ 1 214 890
Total -€ 9 241 102
Impact of vaccination (100% coverage) on direct medical costs and indirect costs from SHI perspective.
SHI statutory health insurance.
*Includes SHI reimbursement for productivity losses associated with medical visits, hospitalisations and nosocomial infections.
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year from the SHI perspective.
With a vaccination coverage rate of 75% (at the lower
end of coverage rates achieved for STIKO-recommended
vaccinations), the projected overall cost saving to the SHI
was estimated at €6.9 million.
Sensitivity analyses
The results of the one-way and the probabilistic multi-way
sensitivity analyses are shown in Figure 2 and Figure 3,
respectively.Figure 2 One-way sensitivity analyses. Tornado diagram showing result
versus no vaccination) in total cost per vaccinated child. The vertical line in
more than €0.Figure 2 shows the effect of the different ranges of the
input variables on the total cost difference (vaccination
versus no vaccination), presented as a tornado diagram.
Three factors were identified that could increase the
incremental cost of vaccination above the cost-neutral
point (i.e., the point at which vaccination would no lon-
ger be a cost-saving intervention). These factors were
the frequency of seeking medical advice, frequency of
rotavirus disease and frequency of hospital visits.
The overall result of the PSA first identifies the spread
of results for the total cost difference. This spread ofs of the one-way sensitivity analyses for the difference (vaccination
dicates where the incremental costs for the vaccine strategy were
Figure 3 Probabilistic sensitivity analysis results. Results of the probabilistic sensitivity analysis, incremental cost (vaccination versus no
vaccination. A: spread of the cost difference. B: cost density curve.
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density curve indicates that around 95% of the results
would lead to an overall cost saving for vaccination
compared with no vaccination (Figure 3B).
Analysis of the 5% of simulations that were not cost-
saving showed that the results were essentially driven
by a few factors: the number of days staying at home
for RVGE, VE against severe disease and frequency of
hospitalisation. This was also supported by the coefficient
values from the regression analysis of the projected
outcome results of the PSA (Figure 4).
Discussion
The base-case results of the model presented here indicate
that full vaccination with the two-dose RIX4414 vaccine
in Germany has the potential to prevent almost 82% of
RVGE cases in a birth cohort over the age range 0–
5 years. As a consequence, rotavirus vaccination would
be expected to produce considerable reductions in
healthcare resource use, costs of hospitalisations andFigure 4 Regression analysis. Coefficients from the regression analysis onphysician visits, and reimbursement of parents’ productivity
losses because of their absence from work to care for a
child with RVGE. The potential savings for the German
SHI are projected to reach a total of €9.2 million for a
birth cohort the size of that in 2008 with 100% vaccination
coverage. With a more realistic vaccination coverage
rate of 75%, the projected savings would be smaller but
still substantial, at around €6.9 million.
Extensive sensitivity analyses were conducted to assess
the effects of uncertainties in the epidemiological and
cost data used in the model. The results of these analyses
support the robustness of the base-case findings. They
indicate that cost savings from rotavirus vaccination
depend on a small number of key factors. The results
underline the importance of the SHI reimbursement
for productivity losses when parents stay at home to
care for a sick child with RVGE. This reimbursement is
a substantial cost, estimated at €18 million for the birth
cohort over a 5-year period, and can be considerably
reduced by vaccination. Other key drivers include highprobabilistic sensitivity analysis results.
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requiring hospitalisation. It is interesting to note the
differences between the one-way and multi-way sensitivity
analyses; the latter illustrates how the different variables
interplay in their effects.
Many cost-effectiveness analyses on rotavirus vaccination
have been published for highly industrialised countries
such as the UK [58], France [25,59], Belgium [60], the
Netherlands [61], Italy [62], and the US [63]. The results
of these analyses are influenced by a variety of factors
such as the cost perspective selected (Ministry of
Health or societal), the time horizon covered (3 years,
5 years or lifetime), and the input values chosen for
health effects (e.g. QALYs), epidemiology and costs.
Results may also be influenced by the organisation and
structure of the healthcare system itself, such as the
ease of access to hospital care (which may affect the
hospitalisation rate), or whether absenteeism for work
is reimbursed [23,64]. Concentrating on analyses from the
perspective of SHI in Germany, the assumed frequency of
rotavirus disease was a key driver for the results presented
here and for the only other available analysis conducted
from this perspective [24]. To the authors’ knowledge, the
model published by Aidelsburger [24] does not correct
the epidemiological data applied for unreported RVGE
cases. The reimbursement of productivity losses due to
paediatric diseases is an interesting feature of the German
healthcare system that has not often been considered in
cost analyses of rotavirus vaccination from the perspective
of third-party payers. It is an important component of
cost for the SHI and, as shown in the results presented
here, it can be reduced substantially by vaccination.
The cost savings from this reimbursement contribute
substantially to reaching the cost-saving threshold for
rotavirus vaccination. The SHI normally reimburses 70%
of the net income of a parent staying away from work
due to caring for a child with an illness, as well as direct
medical costs. Obtaining SHI reimbursement requires a
sickness certificate, but unfortunately there are no precise
data available on reimbursement requests by disease
type in children. In the modelling exercise described
here, we assumed that all families in which both parents
are employed will claim reimbursement from the SHI
for caring for their sick child, and that no other reim-
bursement will be requested. We adopted a conservative
estimate of 31% for the proportion of families with both
parents working. This is based on the numbers of working
mothers reported by the Federal Statistical Office of
Germany for 2008. As this percentage is steadily rising
over time, the impact on the SHI healthcare budget of
sick leave due to rotavirus infection may increase in
the future.
The model selected and the analysis performed have
some limitations. The model was not designed to evaluateefficacy against individual rotavirus strains. It is known
that the diversity of rotavirus strains circulating in the
European population is high and varies by area and
time, so it is possible that the results of the clinical trial
from which we obtained VE data may not be appropriate
for Germany. However, a high level of cross-reactivity
against different circulating strains has been reported
for the two-dose vaccine. Moreover, the sensitivity analysis
indicates that the main driver of the cost results is the
frequency of disease, with the VE range tested having a
much smaller influence on the results.
It could be considered that we have omitted a reduction
of VE over time, as seen in the European trial during
the second year of observation. However, although this
phenomenon is frequently suggested and reported as
due to vaccine waning over time, it may be better
understood as a process of increasing natural immunity
over time in the control group. This would have the effect
of reducing the difference between the vaccinated and
unvaccinated groups in a trial as more time elapses.
Observed data from Belgium after the introduction of
rotavirus vaccination indicated no vaccine waning ef-
fect for the period studied (first four years after vaccine
introduction) [65]. Therefore, the net difference in efficacy
between the vaccinated and unvaccinated cohorts is
measured and expressed over time in the model, and is
not a process of vaccine waning.
Finally, our model is not a dynamic transmission model
and so does not take account of any herd effects. It may
therefore underestimate the effectiveness of vaccination
against rotavirus when the coverage rate is less than 100%.
Following the introduction of rotavirus vaccination in the
US and a universal mass vaccination program in Austria,
decreases in hospitalisations for rotavirus and gastro-
enteritis with no specified cause were observed among
unvaccinated children and young adults (aged <24 years)
[66,67]. In Belgium, rotavirus-related hospitalisations
decreased after the introduction of rotavirus vaccination
not only in the target age group for vaccination but
also in unvaccinated children too young and too old to
receive vaccination, indicating a herd protection effect
[68]. In the US, it has been estimated that about 15% of
the reduction in total hospitalisation and 20% of the
reduction in direct medical cost attributable to rotavirus
vaccination programmes occurred in unvaccinated 5–
24 year-olds [66]. According to data from the Robert
Koch Institut, the age group with the second highest
number of rotavirus cases in Germany is the group
aged 70 years and over (4600 rotavirus cases in 2012,
compared with 19,299 in the age group 0–4 years) [69].
If herd effect could reduce the spread of rotavirus
transmission to this age group, it has the potential to
produce a sizeable reduction in the number of rotavirus
cases in the elderly population in Germany. This could be
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http://www.healtheconomicsreview.com/content/3/1/27an additional benefit of vaccination, but is not included
in the model.
Conclusions
Full vaccination against rotavirus in Germany with RIX4414
has the potential to prevent almost 82% of RVGE-related
diarrhoea events in children aged 5 years and younger.
Rotavirus vaccination costs for the SHI could be fully
offset by the cost avoided in hospitalisations, physician
visits, and SHI-reimbursed productivity losses. With a
more realistic vaccination coverage rate of 75%, vaccination
would still achieve substantial cost savings for the SHI.
Possible indirect effects of rotavirus vaccination, such as
herd protection in age groups not targeted for vaccination
(e.g. elderly people) and in unvaccinated individuals in
the target age group when vaccine coverage is <100%,
could further increase the potential for cost savings.
Endnotes
aRotarix is a registered trade mark of the GlaxoSmithKline
group of companies.
bRotaTeq is a trademark of Merck & Co. Inc.
cRoutine rotavirus vaccination was recommended by
STIKO on 4 July 2013, after this manuscript was first
submitted.
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